|View printer-friendly version|
|Kala Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference|
To access a live webcast and subsequent archived recording of the presentation, please visit the “Investors & Media” section on the Kala website at http://kalarx.com/.
About Kala Pharmaceuticals, Inc.
Kala is a biopharmaceutical company focused on the development and
commercialization of therapeutics using its proprietary
mucus-penetrating particle (MPP) technology, with an initial focus on
the treatment of eye diseases. Kala has applied the MPP technology to a
corticosteroid designed for ocular applications, resulting in two lead
product candidates. The product candidates are INVELTYSTM
(KPI-121 1%) for the treatment of inflammation and pain following ocular
surgery, for which an NDA has been accepted for review by the
Investors and Media: